Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announces it has entered into a definitive agreement to acquire select assets from Intermountain Precision Genomics’ (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah where the Precise Tumor Test is currently performed. The acquisition is expected to close on February 1, 2024, subject to customary closing conditions. By bringing the Precise Tumor and Precise Liquid tests in house, Myriad will open up new opportunities for innovation, growth, and continued development of its oncology portfolio.
Read the full article: Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics //
Source: https://www.globenewswire.com/news-release/2024/01/18/2812030/15459/en/Myriad-Genetics-to-Acquire-Precise-Tumor-Precise-Liquid-and-Laboratory-from-Intermountain-Precision-Genomics.html